Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 169–175 of 175
BioAge is advancing BGE-102, an oral NLRP3 inflammasome inhibitor, into Phase 2 trials for atherosclerotic cardiovascular disease and retinal disease based on Phase 1 data showing tolerability and reductions in inflammatory markers. NLRP3 inhibition represents a mechanistic approach to reducing systemic inflammation implicated in multiple age-related conditions.
AlzeCure completed Phase Ib evaluation of ACD856, a candidate that modulates BDNF and NGF signaling across the blood-brain barrier. Preclinical evidence suggests neuroprotective and anti-inflammatory effects with potential disease-modifying capacity in cognitive decline and depression.
TOS-358, a selective mTOR complex 1 inhibitor, demonstrated a 50% clinical benefit rate and 75% disease control rate in Phase 1a testing, with a notably favorable safety profile compared to existing PI3K/AKT/mTOR pathway inhibitors. The compound showed efficacy in patients resistant or intolerant to standard therapies in this class, positioning it as a potential therapeutic option for advanced malignancies.
Airna initiated a Phase 1 trial of AIR-001, an RNA-editing therapeutic designed to correct the genetic mutation underlying alpha-1 antitrypsin deficiency by restoring functional AAT protein production. This approach addresses a monogenic disorder affecting both pulmonary and hepatic function, representing a mechanistic advance in treating a condition with significant longevity impact across multiple organ systems.
Proteomic analysis identifies distinct and overlapping protein signatures across different manifestations of cerebral small-vessel disease, revealing shared involvement of vascular, immune, and neuronal pathways. Plasma protein panels show predictive capacity for cerebrovascular events, establishing measurable biomarkers for disease stratification and risk assessment.
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.
Excessive daytime napping—particularly longer duration and morning timing—associates with increased mortality risk in older adults, with effects comparable to accelerated aging. The relationship appears driven by underlying systemic dysfunction rather than sleep disorder alone, making napping patterns a measurable indicator of health status.
